0001209191-22-041084.txt : 20220706
0001209191-22-041084.hdr.sgml : 20220706
20220706161225
ACCESSION NUMBER: 0001209191-22-041084
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220702
FILED AS OF DATE: 20220706
DATE AS OF CHANGE: 20220706
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SWAIN PAULA J
CENTRAL INDEX KEY: 0001236934
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12400
FILM NUMBER: 221068815
MAIL ADDRESS:
STREET 1: C/O INCYTE CORPORATION
STREET 2: 3160 PORTER DRIVE
CITY: PALO LATO
STATE: CA
ZIP: 94304
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INCYTE CORP
CENTRAL INDEX KEY: 0000879169
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 943136539
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
BUSINESS PHONE: 3024986700
MAIL ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE CORP
DATE OF NAME CHANGE: 20030318
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE GENOMICS INC
DATE OF NAME CHANGE: 20000710
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930902
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-07-02
0
0000879169
INCYTE CORP
INCY
0001236934
SWAIN PAULA J
1801 AUGUSTINE CUT-OFF
WILMINGTON
DE
19803
0
1
0
0
EVP, Human Resources
Common Stock
2022-07-02
4
A
0
9921
0.00
A
82292
D
Common Stock
2022-07-05
4
F
0
2599
79.25
D
79693
D
Employee Stock Option (right to buy)
77.67
2022-07-02
4
A
0
13443
0.00
A
2032-07-01
Common Stock
13443
13443
D
Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Paula Swain's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.
Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.
Including the July 2, 2022 RSU Grant, this includes an aggregate of 25,227 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.
Beginning July 2, 2022, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
/s/ Elizabeth Feeney, Attorney-In-Fact
2022-07-06